Methods: 99 patients underwent TAVI (78.8% trans-femoral, 12.1% trans-apical/aortic and 9.1% subclavian access) between February 2009 and September 2011 at Rennes University Hospital. Creatinine level was assessed daily at least up to 72 hours after TAVI. the characteristics of patients, procedural features and outcomes according to VARC definitions were studied to evaluate determinants and prognostic impact of AKI. Results: AKI occurred in 22 patients (22.2%). Among them, 5 were AKI 2 (5.1%), 8 were AKI 3 (9.1%) including 4 who needed dialysis (4%). At baseline, compared to no AKI or AKI 1, AKI 2 or 3 patients had a higher prevalence of Ն grade 2 mitral regurgitation (pϭ0.03). There was a non significant trend toward a higher prevalence of moderate or severe chronic kidney disease (pϭ0.07). During the post TAVI hospitalization, AKI 2 or 3 was related to a higher rate of death from any cause (pϭ0.0009), major bleeding, acute heart failure (both pϭ0.002), infectious complications (pϭ0.0008) and longer total and ICU hospitalization duration (pϭ0.0004 and Ͻ0.0001 respectively). There was no association between any stage of AKI and the 30-day and 6-months rate of death. Only AKI 3 was associated with a higher risk of 6-months NYHA class III or IV (pϭ0.016). Conclusions: AKI 2 or 3 as defined by the VARC criteria were associated with a higher risk of post procedural death because of their association with other major post procedural complications. AKI 3 was associated with a higher risk of short term worse functional outcomes.
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Trend of clinical outcomes in patients with chronic kidney disease and endstage renal disease following percutaneous coronary intervention.
James Lai 1 , M. Chadi Alraies 1 , Wael Aljaroudi 1 , Stephen Ellis 1 , Leslie Cho 1 1 Cleveland Clinic, Cleveland, OH Background: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) have been demonstrated to be associated with poor outcomes following percutaneous coronary intervention (PCI). Although there have been significant advances in PCI, patients with CKD/ESRD are often excluded from the majority of published trials. To date, little is known about the trend of clinical outcomes in this population who have undergone PCI. Methods: We analyzed data from 2,470 patients with CKD or ESRD who underwent PCI at The Cleveland Clinic between 1992 and 2011. The primary outcomes of our study were the hard endpoints of all-cause death at 30 days, myocardial infarction (MI), stroke, bleeding, and the composite of major adverse cardiovascular events (MACE), defined as all-cause death at 30 days, MI, stroke, and bleeding. Patients were stratified into 3 groups according to the time of their intervention: group 1 (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) , group 2 (2001) (2002) (2003) (2004) (2005) (2006) , and group 3 (2007) (2008) (2009) (2010) (2011) . Results: Results are shown in Table 1 . Over the 12 year period, there was a significant decrease in the rates of bleeding (group 1: 19.3%, group 2: 12.6%, group 3: 9.3%, pϽ0.00001), MI (7.7%, 3.9%, 2.0%, pϽ 0.0001) and MACE (27.1%, 18.3%, 15.1%, pϽ0.00001). Although rates of stroke and mortality were lower in the 2 most recent cohorts compared with those patients treated before, this trend was not statistically significant.
Conclusions:
In a large registry of patients with CKD and ESRD who have undergone PCI, the trend in clinical outcomes of bleeding and MI have improved over a span of 12 years. Further studies are warranted to understand contributing factors for these improvements. 
TCT-141
Age, Glomerular Filtration Rate, Ejection Fraction and the AGEF score are predictors of Contrast-Induced Nephropathy (CIN) in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
